港股異動 | 中國飛鶴(6186.HK)漲超3% 中期純利同比增長57%
格隆匯8月19日丨中國飛鶴(6186.HK)一度漲超6%,現報17.2港元,漲幅收窄至3.24%,暫成交7.2億港元,最新總市值1536億港元。中國飛鶴昨日晚間發佈中期業績稱,期內收益為87.07億元(人民幣,下同),同比增長48%;母公司擁有人應占期內溢利為27.53億元,同比增長57%;每股基本盈利為0.31元;及每股攤薄盈利為0.30元。集團的毛利率由2019年同期的67.5%增加至期內的70.9%,主要因為集團的高端嬰幼兒配方奶粉產品系列(在其產品中有相對較高的毛利率)於期內的銷售在集團總銷售中的佔比與2019年同期相比有所增加。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.